AstraZeneca forced to clarify deal terms in row with university

AstraZeneca and Kudos must disclose alternative deal structures by October 2025 | Ruling aims to clarify counterfactual damages defence ahead of expert meetings.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK gets appeal go-ahead in licensing clash with AZ

13 February 2024 Appeals court sides with GSK unit in licensing dispute over ovarian cancer drug | Judges find fault with previous decision ordering the pharma firm to pay royalties on all sales of an ovarian cancer treatment.

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Biotechnology

AstraZeneca inks $730m licensing deal for rare heart disease treatment

11 January 2022 Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.

More on this story

Big Pharma

GSK gets appeal go-ahead in licensing clash with AZ

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Biotechnology

AstraZeneca inks $730m licensing deal for rare heart disease treatment

More on this story

Big Pharma

GSK gets appeal go-ahead in licensing clash with AZ

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Biotechnology

AstraZeneca inks $730m licensing deal for rare heart disease treatment